Clinical Trial Update: Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update notes a modular Phase 2/Phase 3 study of sEphB4-HSA in EphrinB2-high solid tumors, with recruitment ongoing for muscle-invasive bladd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• sEphB4-HSA

Snippet

Sponsor: Vasgene Therapeutics, Inc | Conditions: Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma | Phase 2, Phase 3 | Status: RECRUITING